Form D · Biotechnology
Vivtex Corp
Cambridge, MA · CIK 0001941119
Offering snapshot reported Aug 19, 2022 · SEC filing
- Reported sold
- $1.8M Offering amount: $1.8M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 5, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 19, 2022 | Initial | $1,800,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-456319
Source: Form D, filed Aug 19, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jacques Barbut | Director |
| Robert Langer | Director |
| Juan Lopez | Executive |
| Giovanni Traverso | Director |
| Thomas Von Erlach | Director, Executive |
| James Winschel | Director, Executive |
| James Wright | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
790 Memorial Drive Suite 300
Cambridge, MA, 02139
Cambridge, MA, 02139